

REVIEW ARTICLE

Open Access

Methylenetetrahydrofolate reductase and psychiatric diseases

Lin Wan¹, Yuhong Li¹, Zhengrong Zhang², Zuoli Sun², Yi He² and Rena Li^{1,2,3}

Abstract

Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme for the critical process of one-carbon metabolism involving folate and homocysteine metabolisms. It is known that some polymorphism of *MTHFR* would result in reduction of MTHFR enzyme activity as well as DNA methylation process, later shown to have significant impacts in various psychiatric diseases. However, it is unclear whether the polymorphism of *MTHFR* could be an independent or an add-on risk factor for specific psychiatric symptoms, such as anxiety, depression, positive, or negative symptoms of schizophrenia, or acts as risk factor for specific psychiatric disorders, such as schizophrenia, major depression, autisms, and bipolar disorders. It is also understudied on whether folate supplements could be an effective treatment for psychiatric patients with defect MTHFR activity. In this review, we not only gathered the most recent discoveries on *MTHFR* polymorphism and related DNA methylation in various psychiatric disorders, but also highlighted the potential relationships between MTHFR activity and implication of folate-related function in specific mental diseases.

Introduction

Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme of folate metabolism in the process of one-carbon metabolism. MTHFR converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate and participate in folate and homocysteine conversion correlated to DNA methylation¹. As consequences of polymorphism of *MTHFR*, reduction of MTHFR enzymatic activity would cause impaired methylation as well as deficiency of folate. There are plenty of relevant studies on linkage between MTHFR and human diseases including cardiovascular diseases, tumors, neurologic diseases, and psychiatric disorders^{2–5}. Moreover, there are stratified factors that have been identified to be involved in the relationship between MTHFR and diseases, such as gender, age, and ethnicity^{6–9}. As both DNA methylation and folate are important in mental health, reduction of MTHFR activity

or folate deficiency have been associated with an onset of several psychiatric diseases¹⁰, schizophrenia, bipolar disorder, depression, autism, and ADHD. In this review, we specifically focus on the *MTHFR* polymorphism and related methylation and folate effects on psychiatric diseases as well as the possibility of relationship between clinical phenotypes of MTHFR-related diseases and effectiveness of clinical treatment in psychiatric patients¹¹.

MTHFR

MTHFR gene

In humans, the *MTHFR* resides on chromosome 1 location p36.3 and was originally described as containing 12 exons as shown in Fig. 1. Human *MTHFR* transcripts are respectively at 2.2 kb, 7.5 kb, and 9.5 kb¹². The cDNA of 2.2 kb-fragment sequence codes for a 656 residue and 70–77 kDa protein¹³. The cDNA of 7.5 kb and 9.5 kb sequence code a second isoform of 77 kDa protein. Among the exons of *MTHFR*, the first one is noncoding¹. Apart from the coding region, variable 5' and 3' non-coding regions (UTR) were identified, resulting in transcript heterogeneity. The 5' and 3' termini of the *MTHFR* cDNA overlap with the 5' terminus of a chloride ion

Correspondence: Rena Li (rl@roskampinstitute.org)

¹Center for Brain Disorders Research, Capital Medical University & Beijing Institute of Brain Disorders, Beijing 100069, China


²The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China

Full list of author information is available at the end of the article.

© The Author(s) 2018



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.



channel gene and the 3' terminus of an unidentified gene, respectively. The *MTHFR* gene has multiple promoters and several polyadenylation sites creating 3'UTR lengths of $0.2 \text{ kb} \pm 5.0 \text{ kb}$ or $0.6 \text{ kb} \pm 4.0 \text{ kb}$ in human¹². The *MTHFR* gene has been identified to possess 14 common or rare single nucleotide polymorphism that are associated with enzymatic deficiency¹⁴. Among them rs1801133(C677T) and rs1801131(A1298C) are most reported that may reduce the *MTHFR* activity in various degrees. For C677T, the enzyme activity of heterozygous and homozygous mutant individuals are respectively 67 and 25% of the wild-type ones. And for A1298C, the enzyme activity of heterozygous and homozygous mutant individuals are respectively 83 and 61% of the wild-type subjects¹⁵, as shown in Fig. 1.

MTHFR and its activity

While *MTHFR* gene codes for different variants, the most common form of *MTHFR* in human is a 656 amino acids protein. Human *MTHFR* consists of an N-terminal catalytic domain (amino acids 1–356) which binds 5,10-methylenetetrahydrofolate (5,10-methylene THF), and a C-terminal regulatory domain (amino acids 363–656) which binds S-adenosylmethionine (AdoMet, SAM)^{16,17}. As shown in Fig. 2, *MTHFR* catalyzes the physiologically irreversible reduction of 5,10-methylene THF to 5-methyltetrahydrofolate (5-methyl THF), and plays a critical role in one-carbon metabolism for the reaction of producing methyl groups to participate in epigenetic regulation¹⁸. The properties and crystal structure of *MTHFR* from the bacterium *Thermus thermophilus* HB8 have been determined¹⁹. While the regulation of *MTHFR* activity is closely controlled by SAM at C-terminal regulatory domain, more studies indicated that the human *MTHFR* enzyme activity is also regulated by multiple phosphorylated sites on a serine-rich N-terminal

extension region²⁰. The phosphorylation leads down-regulation of *MTHFR* activity and upregulation of allosteric inhibition by SAM. It is suggested that phosphorylation impacts on the allosteric regulation of *MTHFR* via altering the equilibrium of active and inactive states of the enzyme, favoring the inactive state which SAM preferentially binds²¹. The active form of *MTHFR* could impact on the generation of 5-methyl THF, which is the active form of folate in vivo. Then methionine level increases and related methyl group donation is driven which successively exert potential mechanism on psychiatric diseases, as shown in Fig. 3.

MTHFR and DNA methylation

Another important role of *MTHFR* is to participate in donating methyl group to regulate epigenetic modification in the one-carbon metabolism. Methylation is a common regulation process of gene expression that influences cellular development and function²², which is dependent on SAM as a methyl donor. SAM originated from methionine cycle in which 5-methyl THF transfers methyl groups to homocysteine in a reaction catalyzed by methionine synthase to produce methionine. In this process, 5,10-methylene THF play a critical role in methionine regeneration and methyl donation, meanwhile *MTHFR* catalyzes the irreversible conversion of 5,10-methylene THF to 5-methyl THF that participate in generation of SAM in methionine cycle and offer methyl group²³.

MTHFR polymorphism

***MTHFR* polymorphisms and enzymatic activity**

There are several sites of *MTHFR* polymorphism that have been reported including 2 enzyme activity associated locuses C677T and A1298C and 6 enzyme activity unassociated locuses⁶. As shown in Table 1, with regard to the




Fig. 2 One-carbon metabolism. MTHFR is a key enzyme to catalyze conversion of 5,10-methylene THF to 5-methyl THF and contribute to generation of SAM, which is the direct donor of methyl group. DHF, dihydrofolate acid; THF, tetrahydrofolate acid; MTHFR, methylenetetrahydrofolate reductase; dTMP, deoxythymidine monophosphate; dUMP, deoxyuridine monophosphate; NADPH, nicotinamide adenine dinucleotide phosphate; FAD, flavine adenine dinucleotide; Met, methionine; Hcy, homocysteine; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine




Fig. 3 Potential mechanisms of MTHFR in psychiatric diseases. Methyl group supply in one-carbon metabolism is affected by MTHFR enzyme catalytic process. MTHFR polymorphism affects downstream methylation of schizophrenia-related proteins. DA, glutamate and so on. BH4, tetrahydrobiopterin; DA, dopamine; NE, norepinephrine; 5-HT, 5-hydroxytryptamine

association of *MTHFR* gene and its enzyme products, some of the studies revealed severe enzymatic deficiency. The encoding of *MTHFR* appears to be polymorphic such as the gene site C677T, one of the most studied and clinically important variant in exon 4. The C677T variant results from a single nucleotide substitution at this position, in which cytosine is replaced by thymine resulting a conversion of alanine to valine residue²⁴. The substitution lowers the affinity of MTHFR and its cofactor, which promotes the thermolability and diminishes the enzyme activity. Comparing with wild genotype (CC), the heterozygote (CT) and mutation homozygote (TT) lead to

the decline of enzyme activity by about 34 and 75%, and increased thermolability in lymphocyte extracts²⁵. In 2001, the Ala222Val mutation was created in human MTHFR, and the mutant protein was successfully purified and its properties were determined. Different from the former studies, the Ala222Val variant exhibits identical catalytic properties as the wild-type enzyme, but it is thermolabile¹⁷.

Another common polymorphism is A1298C, in which adenine is replaced by cytosine resulting a conversion of glutamate to alanine at 429 residue, which also diminishes the enzyme activity. Lymphocyte extracts from

Table 1 MTHFR and Psychiatric diseases

Gene locus	Diagnosis	Subjects (F/M)	Mean age (F/M)	Genotype number	Allele number	Comments	Country	Year [Ref.]
C677T	SCZ	SCZ 200(99/101)	32.7±9.6	CC 113, CT 68, TT 19	C 294, T 106 C	1.5 and 1.7-fold times higher distribution of T allele in SCZ and BD patients, SCZ patients TT was 2.5 times higher than controls.	Poland	2006 ⁴⁶
	BPD	BPD 200(95/105)	46.0±43.5	CC 108, CT 73, TT 19	289, T 111 C			
SCZ	Controls	300(141/151)	31.0±29.5	CC 210, CT 79, TT 11	499, T 101	TT genotype associated with an increased of schizophrenia, CT compared to CC subjects accounted for an increased of schizophrenia	Netherlands	2005 ⁴⁵
	Patients	254(71/183)	41 ± 14	CC 112, CT 111, TT 31	C 335, T 173			
SCZ	Controls	414(236/178)	51 ± 14	CC 212, CT 166, TT 36	C 590, T 238	Increased 677T allele load confers risk for negative symptoms in SCZ TT exhibited significantly greater deficits on VFT, had more difficulty achieving the first category on the WCST and did not differ in CVLT.	USA	2006 ⁴⁷
	Patients	200(94/106)	43.4	CC 97, CT82, TT 21	C276, T124			
SCZ	Patients	200(62/138)	43.4	CC 97, CT82, TT 21	C276, T124	Patients of the C677T significantly affected age at onset of schizophrenia with lower age of onset with increasing numbers of the mutant T allele.	Scandinavian & Chinese	2009 ⁴⁹
SCZ	Scandinavian	820(341/479)		CC 401, CT 342, TT 76	C 1144, T 494			
SCZ	Chinese	243(120/123)	37 ± 10	CC 47, CT26, TT 12	C 120, T 50	A significant association for MTHFR 677TT in the male, and 677CT genotype in the total patients group.	Syria	2012 ⁵¹
SCZ	Patients	85(60/25)	40 ± 10	CC 58, CT58, TT 10				
SCZ	Controls	126(47/79)	31.2 ± 9.9	CC 160, CT 450, TT 384	C 770, T 1218	677T allele have effect on risk of schizophrenia, memory impairment, and gray matter density.	China	2013 ⁵²
SCZ	Controls	1036(434/602)	32.5 ± 8.3	CC 213, CT 505, TT 318	C 931, T 1141			
SCZ	Controls	1149(473/676)	54.6 ± 14.9	CC 417, CT 530, TT 202	C 1364, T 934	a significant association between the MTHFR C677T polymorphism and schizophrenia.	Japan	2014 ⁵³
SCZ	Controls	2742(1512/1230)	38.8 ± 12.6	CC1072,CT1260, TT 410	C3404, T 2080			
SCZ	Controls	621(319/302)	46.5 ± 15.8	CC 220, CT 309, TT 92	C 749, T 493			
SCZ	controls	486(255/231)	35.0 ± 12.7	CC 174, CT 239, TT 73	C 587, T 385	A weak haplotype analysis association for the 1298C-677C haplotype.	China	2010 ⁶⁰
SCZ	Cases	143		CC51, CT 70, TT 22	C 172, T 114			
SCZ	Controls	235		CC 71, CT 123, TT 41	C 265, T 205			
SCZ	Cases	90(32/58)	42.91	CC40, CT 37, TT 12	C 117, T 61	MTHFR polymorphisms interacted on cognition, and the MTHFR T allele attenuated the cognitive effects.	Greece	2013 ⁹⁷
SCZ	Controls	55(25/30)	43.69	CC 21, CT 22, TT 12	C 64, T 46			
SCZ	Cases	696				MTHFR polymorphisms are not related to the development of schizophrenia strong support for association of C677T with schizophrenia.	Japan	2010 ⁶
SCZ	Controls	747						
SCZ	Cases	3213						
SCZ	Cases	742(185/557)	39.0 ± 14	CC 334, CT 322, TT 86	C 990, T 494	MTHFR polymorphisms do not influence age of onset in schizophrenia Neither winter birth nor MTHFR were significantly associated with increased schizophrenia risk	East Asia & Caucasias	2010 ⁷
SCZ	Controls	884(477/407)	52.0 ± 20	CC 405, CT 387, TT 92	C 1197, T 571		Netherlands	2007 ⁸
SCZ	SCZ	103(55/68)	33.9 ± 9.4	CC 52, CT 36, TT 15	C 140, T 66			
SCZ	BD	134(62/72)	32.2 ± 10.9	CC 46, CT 70, TT 18	C 162, T 106	MTHFR C677T polymorphisms are associated with the risk of developing BD and schizophrenia and influence the age at onset of BD but not schizophrenia.	Egypt	2014 ⁶²
BPD	Controls	149(73/76)	34.3 ± 6.0	CC 114, CT 30, TT 5	C 258, T 40			
BPD	Cases	501	37.8 ± 12.7	CC 178, CT 231, TT 73	C 587, T 415	MTHFR C677T variant was not to play a major role in the susceptibility to bipolar disorder.	China	2009 ⁶⁴
BPD	Controls	461	36.6 ± 7.2	CC 153, CT 235, TT 92	C 541, T 381			
BPD	Cases	846(533/293)	47.2 ± 11.9	CC 362, CT 386, TT 98	C 1110, T 582			
BPD	Controls	1576(906/670)	42.1 ± 13.2	CC 642, CT 719, TT 215	C2003, T 1149	No association for genotypic or allelic in this sample.	UK	2010 ⁶⁵
SCZ	Cases	66(21/45)	29.0 ± 4.0	CC 35, CT 27, TT 4	C 97, T 35	failed to find interaction between C677T polymorphism and vulnerability to schizophrenia and bipolar disorder.	Iran	2011 ⁶⁶
BPD	Cases	90(39/51)	35.0 ± 8.0	CC 52, CT 34, TT 4	C 138, T 42			
DD	Controls	94(41/53)	31.0 ± 6.0	CC 54, CT 38, TT 2	C 146, T 42			
DD	Cases	100(63/37)	47.7 (18-83)	CC 30, CT 56, TT 14	C 116, T 84	C677T genotype associated with increased risk of depressive episodes in this study.	UK	2004 ⁶⁷
MDD	Controls	89(51/38)	51.2 (25-84)	CC 40, CT 37, TT 12	C 117, T 61			
MDD	Cases	147(103/44)	47.4 ± 11.3	CC 63, CT 68, TT 16	C 194, T 100	677CC genotype showing the most severe symptom severity course over the 60 months of observation.	Australia	2013 ⁶⁸
MDD	Cases	368(278/90)	51.54 ± 16.40	CC 88, CT 259, TT 21	C 435, T 301	The T allele and CT genotype of C677T were different between cases and controls.	China	2014 ⁷⁵
MDD	Controls	219(139/80)	44.42 ± 16.52	CC 113, CT 91, TT 15	C 317, T 121			

Table 1 continued

Gene locus	Diagnosis	Subjects (F/M)	Mean age (F/M)	Genotype number	Allele number	Comments	Country	Year [Ref.]
Anxiety	DD	Cases 621(431/190)	Cases 83	CC 308, CT 263, TT 50	C 879, T 363	TT genotype was significantly related to depression without comorbid anxiety and no significant association to anxiety.	Norway	2003 ⁶⁹
		Cases 242(100/142)		CC 127, CT 85, TT 30	C 339, T 145			
2008 ⁷⁰	DD	DD (postmenopausal)	Cases 83	54.2±4.7 (cases + controls)	CC 26, CT 38, TT 19	C 90, T 76	TT genotype displayed a 4.831-fold increased risk of moderate and severe depression.	Poland
		C 128, T 50		CC3035, CT3017, TT757	C9087, T4631			
DD	DD	Pregnancies 6809	28.3±4.71	CC3035, CT3017, TT757	C9087, T4631	Pregnancies folic acid supplements protected against depression, more obvious in TT genotype.	UK	2011 ⁸⁸
		cases 4992	controls 17082 in 26 studies					
DD in TCEs	DD	Cases 124(92/32)	44.5	CC 60, CT 50, TT 14	C 170, T 78	MTHFR C677T polymorphism contributed to the increased depression risk in overall populations	East Asia & Caucasias	2013 ⁷³
		Controls 665(372/293)	20.5	CC 306, CT 239, TT 20	C 751, T 279			
DD	DD	NAME 1017(768/249)	75.3	CC + CT 906, TT 111	C 96, T 68	T-allele carriers may be at an increased risk for MDD recurrence after exposure to TCEs.	Netherlands	2013 ⁷¹
		BRRHS 939(674/265)	57.9	CC + CT 823, TT 116	C 96, T 68			
DD	DD	Cases 82	74.7±4.4	CC 31, CT 34, TT 17	C 94, T 54	did not find an association between the TT genotype and impaired cognition or depression.	USA	2012 ⁷⁶
		Controls 74		CC 33, CT 28, TT 13	C 94, T 54			
DILD&Anxiety	MDD	Cases 240	74.7±4.4	CC 98, CT 113, TT 29	C 309, T 171	No significant differences were found in frequency of the T allele or the MTHFR C667T TT genotype between the depressed and controls.	USA	2011 ⁷⁷
		Cases 1222(841/381)		CC 545, CT 513, TT 164	C 1603, T 841			
MDD	MDD	Controls 835(464/371)	47.2±12.0 (46.59±12.31/48.59±11.71)	CC 350, CT 379, TT 106	C 1079, T 591	C677T gene variation does not play a role in the modulation of mood and cognitive performance.	Australia	2005 ⁷⁸
		Cases 39(8/31)	8.83±0.84	CC 21, CT 14, TT 4	C 56, T 22			
ASD	ASD	Controls 43(14/29)	9.05±0.91	CC 25, CT 15, TT 3	C 65, T 21	a normal distribution of polymorphism in ASDs, but the frequency of T allele was more prevalent.	Romania	2009 ⁸⁰
		Cases 147(40/107)	7.9±4.5	CC 65, CT 62, TT 20	C 192, T 102			
ASD	ASD	ASD 429(67/372)	8.1±4.3	CC 79, CT 77, TT 30	C 235, T 137	four behaviors were more common and at least one copy of T allele as compared to homozygous wildtype individuals. No differences existed among genotypes for level of functioning	USA	2009 ⁸¹
		DD 130(44/86)		8.2±4.1	CC 87, CT 83, TT 16			
ASD	ASD	TD 278(50/228)	8.2±4.1	CC 76, CT 136, TT 37	C 288, T 210	Periconceptional folic acid may reduce ASD risk in those with inefficient folate metabolism.	USA	2012 ⁸⁹
		Cases 186(48/138)		8.1±4.3	CC 139, CT 204, TT 80			
ASD	ASD	Controls 186(45/141)	8.2±4.1	CC 60, CT 68, TT 23	C 188, T 114	The TT frequency in children with autism was significantly higher than those in controls.	China	2012 ⁸³
		Cases 249(24/225)		8.2±4.1	CC 45, CT 41, TT 14			
ASD	ASD	Controls 423(169/254)	6.0±2.1	CC 44, CT 51, TT 3	C 139, T 57	677CT/1298AC was significantly associated with an risk of ASD by 2.11-fold to 677CC/1298AA in males but not females	Korea	2014 ⁸⁴
		Cases 151(35/116)		5.0±1.0	CC 37, CT 33, TT 0			
ASD	ADHD	Controls 100(43/57)	4.1±4.2	CC 23, CT + TT 25	CC 107, T 33	The genotypes did not show differences between cases and controls, nor association between the T allele and selected behaviors.	Brazil	2010 ¹⁰⁰
		Cases 98(27/71)		6.0±2.1	CC 22, CT + TT 18			
ADHD	ADHD	Controls 702(4/46)	4.1±4.2	CC 22, CT + TT 18	CC 15, CT + TT 15	a 1.3-fold increase for C677T locus predominant linkage to the inattentive symptoms.	USA	2008 ⁸⁵
		Cases 48(16/32)		9.77±2.3	CC 15, CT + TT 15			
ADHD	ADHD	Cases 40(9/31)	10.5±4.5	CC 15, CT + TT 15	CC 15, CT + TT 15	no significant differences in genotype distributions of the C677T alleles between ADHD and controls.	Turkey	2011 ⁸⁶
		Controls 300(7/23)		10.5±4.5	CC 15, CT + TT 15			
ADHD	ADHD	Cases 580(52/528)	8.87±2.55	CC 154, CT 125, TT 21	C 433, T 167	the folate-homocysteine pathway gene variants may affect ADHD through mild hyperhomocysteinemia and vitamin B12 deficiency.	India	2017 ¹⁰²
		Controls 286(156/130)		8.02±2.69	CC 44, CT 47, TT 9			
ADHD	ADHD	Cases 100(20/80)	8.02±2.69	CC 154, CT 125, TT 21	C 433, T 167	Turkey	2012 ⁸⁷	2017 ¹⁰²
		Controls 300(60/240)		8.02±2.69	did not find any association between MTHFR 677 T allele, MTHFR			

Table 1 continued

Gene locus	Diagnosis	Subjects (F/M)	Mean age (F/M)	Genotype number	Allele number	Comments	Country	Year [Ref.]
A1298C	SCZ	Cases 200(94/106)	43.4	AA 99, AC83, CC 18	1298C allele, and ADHD; A281, T119	No significant role for the A1298C polymorphism in schizophrenia symptoms. an association between the 1298C allele and SCZ	USA	2006 ⁴⁷
		Cases 379(159/220) Controls 380(165/215)	32.1 ± 9.7 31.5 ± 8.6	AA230, AC127, CC22 AA260, AC108, CC12 AA88, AC49, CC6 AA171, AC61, CC3	A587, C171 A628, C132 A225, C61 A403, C67			China
	SCZ	Cases 143 Controls 235		AA69, AC63, CC15 AA 147, AC 75, CC 14	A201, T93 A369, C103	maternal <i>MTHFR</i> 1298C allele associated with a significantly increased risk of schizophrenia.	China	2010 ⁶⁰
		Cases 147(103/44) Cases 249(242/25) Controls 423(169/254)	47.4 ± 11.3	AA 298, AC 114, CC 11 AA 25, AC +CC 23	A201, T93 A369, C103 A710, C136	No association between A1298C and MDD significant associations between autistic disorder or atypical autism and 1298AC polymorphism	Australia Korea	2013 ⁶⁸ 2014 ⁸⁴
	ADHD	Cases 48(16/32)	4.1 ± 4.2	AA 9, AC +CC 31 AA 14, AC +CC 16		A1298C was predominant linkage to inattentive symptoms, a 7.4-fold increase in diagnosis.	USA	2008 ⁸⁵
	ADHD	Cases 40(9/31) Controls 30(7/23)	9.77 ± 2.3 10.5 ± 4.5			A1298C alleles was different between the ADHD patients and the controls.	Turkey	2011 ⁸⁶

SCZ schizophrenia, *BPD* bipolar disorder, *MDD* major depression disorder, *NAME* the nutrition, aging, and memory in elders, *BPPHS* the Boston Puerto Rican Health Study, *ASD* Autism spectrum disorders, *ADHD* attention deficit hyperactivity disorder, *MID* mood disorder, *TCEs* traumatic childhood events, *DLI* development delay, *TD* typical development, *AD* Alzheimer disease, *MCI* mild cognition impairment

homozygous 1298CC individuals showed 61% of wild-type enzyme activity²⁶. The Ala177Val was established in the *MTHFR* of *E. coli* to study the biochemical phenotype of the Ala222Val variant. Then literatures reported the Ala177Val mutation has no influence on the kinetic parameters of bacterial *MTHFR*, but rather reduces enzyme stability and affinity for cofactor, and thus increases the tendency to form inactive enzyme via flavin dissociation, compared to the wild-type enzyme²⁷.

***MTHFR* polymorphism and methylation**

MTHFR polymorphism is also associated with global methylation activity. For example, a study of coronary artery patients indicated that genomic DNA methylation directly correlates with folate status and inversely with plasma homocysteine levels. After genotype analysis, TT genotypes had a diminished level of global DNA methylation compared with those with CC wild type²⁸. Such a change was also found in healthy individuals which showed reduction of DNA methylation in individuals with the TT *MTHFR* genotype compared to subjects with CC *MTHFR*²⁹. While DNA methylation may be age, gender, and cell-type specific, *MTHFR* polymorphism might not be always associated with hypomethylation of DNA. For example, a study of aging-related DNA methylation found hypomethylation in aged individuals compared to young populations without significant association with C677T *MTHFR* genotypes³⁰. Studies also demonstrated no significant inference of *MTHFR* C677T polymorphism in global DNA methylation in oral epithelial cell samples³¹ or lymphocytes of healthy individuals³², as well as cutaneous squamous cell carcinoma in renal transplant patients³³. Those reports suggested a *MTHFR* polymorphism independent mechanism in aging and cell-type specific global DNA methylation. Furthermore, a similar results were reported in a study of individuals with or without oligozoospermic which showed no significant association between DNA methylation in spermatozoa and the *MTHFR* C677T genotypes although a trend for higher incidence of methylation alterations in severe oligozoospermic infertile men with CT genotypes were observed³⁴, suggesting that a much more complicated or indirect interactions between *MTHFR* polymorphism and methylation are involved.

As global DNA methylation refers to the average methylation status that occurs across the whole genome, *MTHFR* polymorphism could also destruct gene-specific methylation process which refers the methylation status of specific genes. For example, a study of *MTHFR* polymorphism genotypes in colorectal cancer patients reported that the frequency of methylated *Bcl-2* promoter was significantly higher in individuals with CC genotype than that of those with CT and TT genotypes, and a significant difference of C and T alleles distribution were observed

between patients with methylated and unmethylated *Bcl-2* promoter³⁵. Furthermore, studies of *IGF-2* gene in transitional cell carcinoma of the bladder and *MGMT* gene in gastric cancer showed that patients with CT or TT *MTHFR* genotypes had reduced methylation of *IGF-2* or *MGMT* compared those with CC genotype^{36,37}. Together, as *MTHFR* is an important enzyme for folate metabolism which plays critical role in epigenetic as DNA methylation, accumulated evidence showed that global DNA methylation can be associated with *MTHFR* polymorphism genotypes in both healthy populations and individuals with various diseases. However, some cell type- and age-related global DNA methylation showed independent of *MTHFR* genotypes. While the underlying mechanism of *MTHFR* independent global DNA methylation remains unknown, the *MTHFR* polymorphisms related gene-specific DNA methylations were commonly reported in various pathological conditions.

Mouse models of MTHFR deficiency

The *Mthfr* of mice were knockout to investigate MTHFR deficient by animal models³⁸. The *Mthfr*^{+/-} mice showed normal growth and similar survival to that of wild-type mice³⁹. The *Mthfr*^{-/-} mice were with none MTHFR enzyme activity in all tissues, whereas the *Mthfr*^{+/-} showed 60% residual activity, similar to the value observed in patients homozygous for the C667T polymorphism⁴⁰. In the *Mthfr*^{+/-} and *Mthfr*^{-/-} mice, the plasma total homocysteine levels were 1.6- and 10-fold higher, respectively, than the wildtype controls. SAM levels were decreased, but S-adenosylhomocysteine (AdoHcy, SAH) levels were elevated considerably, with global DNA hypomethylation observed in both heterozygotes and homozygotes³⁸. Then researchers proposed that heterozygous knockout mice appeared to be a good animal model for individuals homozygous for the C667T polymorphism, whereas the homozygous null mice were a better one for severely MTHFR-deficient individuals¹⁹. Apart from human studies, mice with heterozygous and homozygous mutation in *Mthfr* C677T still accompany with global DNA hypomethylation, decreased SAM and increased SAH levels⁴¹.

MTHFR polymorphism and psychiatric diseases

Extensive clinical studies demonstrated a significant linkage between *MTHFR* polymorphism and various diseases, such as cardiovascular diseases, neuronal developmental diseases, cancers as well as psychiatric disorders. Among which, C677T and A1298C polymorphisms of *MTHFR* have been studied the most in psychiatric diseases and showed significant association with reduction of MTHFR enzymatic activity and methylation. In this session, we will focus on the polymorphisms in the gene encoding for MTHFR in schizophrenia (SZ), bipolar

disorder (BPD), depression, autism disorder (ASD) and attention deficit hyperactivity disorder (ADHD). Table 1. summarizes studies including MTHFR polymorphism and psychiatric diseases involved in this review.

Schizophrenia

For decades ago, there was a report of MTHFR enzymatic activity reduction in two schizophrenia patients which were 18 and 21% percent of the normal level, respectively, while homocysteine remethylation was also defected⁴². Later, a regression model was created in a study of *MTHFR* C677T genotype and DNA methylation in schizophrenia subjects, which found females with TT genotype were associated with the lowest global methylation⁴³.

Amounts of studies have demonstrated that the level of *MTHFR* polymorphism in C677T locus is associated with the risk of schizophrenia. As indicated in a meta-analysis of *MTHFR* consisted of 7 studies, individuals carried with TT homozygotes had the greatest risk of schizophrenia, compared to the subjects with CC wild type and CT heterozygous genotypes⁴⁴. An allele study with well-defined patients and healthy controls indicated that people with CT heterozygotes had the higher risk of schizophrenia than CC carriers⁴⁵. Furthermore, a genotype study also reported that homozygous TT genotype of *MTHFR* was also associated with risk of schizophrenic patients accompanying with bipolar disorder⁴⁶.

It is interesting to mention that the C677T polymorphisms of *MTHFR* also has an influence on symptoms of schizophrenia. For example, an increased T allele load is linked to the increase severity of negative symptoms in schizophrenia, while reducing severity of positive symptoms were also noticed. However, the effect of T allele on the negative symptoms of schizophrenia could be further enhanced by folate deficiency⁴⁷. Furthermore, comparing with CC and CT, schizophrenia patients with TT genotype exhibited greater deficits on the verbal fluency test (VFT) and more difficulties on the Wisconsin Card Sorting Test (WCST), but not in California Verbal Learning Test (CVLT) performance⁴⁸. However, the effect of C677T polymorphisms of *MTHFR* on cognitive function was not significant in normal subjects as a longitudinal cognitive study showed that the *MTHFR* C677T polymorphism was not associated with cognitive performance at baseline or over 12 years⁴⁹. In addition, studies also demonstrated that the C677T polymorphism of *MTHFR* is associated with onset age of schizophrenia in a dose-dependent manner, such as increasing numbers of the mutant T allele is linked with early onset⁵⁰.

The relationship between *MTHFR* polymorphism and schizophrenia in different ethnic population were also investigated. Study of schizophrenic patients and healthy controls in the Arab population from Syria found a strong

association between C677T and schizophrenia, which showed higher variant T allele frequency in the patients group. Interestingly, a statistically significant association was found for 677TT genotype under the recessive model in the male patients subgroup, and CT genotype under the overdominant model in the total patients group⁵¹. Studies of Chinese Han population indicated that the T allele shown associated with schizophrenia as a risk allele⁵² while a case–control association between the *MTHFR* C677T polymorphism and schizophrenia in a Japanese subjects research also demonstrated a strong linkage between the *MTHFR* C677T polymorphism and schizophrenia⁵³. Furthermore, a meta-analysis including 38 studies with schizophrenia cases and controls showed the association between C677T polymorphism and risk of schizophrenia in all three ethnic populations—African, Asian, and Caucasian⁵⁴.

Studies of sex differences in *MTHFR* polymorphism might provide some insights for the divergent results from various studies of psychiatric disorders. A strong association between 677T allele and male patients with schizophrenia compared female patients suggest that 677T allele might represent different liability in genders⁴⁶. While little is known on the sex differences in *MTHFR* polymorphisms, sex hormones, such as estrogen is known to play a protective effect in female patients with schizophrenia as for the impact of neurodevelopment and social maturation⁵⁵. On the other hand, testosterone may increase male vulnerability to an adverse illness course compared to estrogen⁵⁶, attributed to its narrower and sometimes unfavorable neuroprotection and neurotransmitter modulation profile⁵⁷. Furthermore, progesterone is reported to benefit neurocognition through enhancement of dopamine release in human males and may also have relevance in male physical and mental health while enhancing the benefits of estrogen through potentiation of estrogen-primed effects on dopamine receptors in male schizophrenic patients⁵⁸.

Except for the C677T, there is another site of *MTHFR* polymorphisms associated with psychiatric disorders. A study with patients of schizophrenia and control subjects showed an association between the A1298C allele and schizophrenia⁵⁹. Another research including 111 families, demonstrated that deficient *MTHFR* enzyme activity in pregnant women was related to the A1298C variant, which was associated with a higher risk of schizophrenia in the offsprings⁶⁰.

Studies of individual with both SNPs (C677T and A1298C) showed that subjects with heterozygosity for both mutations resulted in an even lower *MTHFR* activity than heterozygosity for single *MTHFR* mutations, while no subjects carry both homozygote for *MTHFR* mutations regardless which SNPs¹⁵. Furthermore, There were studies of multiple polymorphisms of one-carbon metabolism

and schizophrenia symptoms showed an increase negative symptoms severity with increase of risk alleles, suggesting a cumulative effects of risk SNPs in one-carbon metabolism⁶¹.

Bipolar disorder

In addition to schizophrenia, study demonstrated an association between homozygous 677TT genotype of *MTHFR* gene and bipolar disorder with stronger linkage in male patients than female patients⁴⁶. Another study found a higher prevalence of C677T polymorphism in BD patients than healthy subjects, while patients with BD with early onset carried one copy of the T allele⁶². A meta-analysis of 56 studies examining *MTHFR* C677T in patients and control subjects indicated that the T allele and TT genotype carriers showed significant increased risk of major psychiatric disorders including schizophrenia and bipolar disorder⁶³. At the same time, some studies found disparate results. For instance, a study reported no significant association between C677T and bipolar disorder⁶⁴, while another study found no evidence for C677T genotypic or allelic association with BD regardless of type I or II⁶⁵. A study with bipolar patients and schizophrenia subjects also observed no robust differences between patients and controls either for allele frequencies or genotype distribution of C677T polymorphism⁶⁶. These discrepancies may result from population stratifications, explicitly, socio-economic status. On the other hand, the included sample size may play a critical role in divergent results.

Depression

Depression is another major psychiatric disease. *MTHFR* polymorphism is also noticed in patients with depression. Studies found that *MTHFR* polymorphisms might be related to the episode and prognosis of depressive disorder, not the stage of the disease. For example, a cohort study of depressive patients and healthy controls found that *MTHFR* polymorphism were more common in the individuals with depression history compared to controls⁶⁷, while a study over a 60-month follow-up with depressed subjects indicated that the CC genotype of *MTHFR* C677T were more likely to have more severe symptoms compared to TT genotype carriers⁶⁸. Another study showed that hyperhomocysteinemia and TT *MTHFR* genotype were significantly related to depression only, not comorbid anxiety disorder⁶⁹. More studies reported that *MTHFR* C677T is associated with risk of depression, such as postmenopausal depression⁷⁰ and childhood trauma related major depression disorder (MDD)⁷¹. It is important to point out the interaction between *MTHFR* polymorphisms and environmental risks for MDD, such as dietary and stress. For example, a study of inter-relationship between *MTHFR* polymorphism and

MDD found that the minor T-allele of *MTHFR* C677T was associated with increased folate deficiency-related body mass index and homocysteine levels in MDD patients only⁷². Another stress-related *MTHFR* polymorphism in MDD study showed that traumatic stress in childhood could increase risk of MDD recurrence as well as the development of more severe depressive symptoms in *MTHFR* TT genotype carriers. This study suggests that the increase of mutant allele number of T in C677T locus will enhance stress risk for depression⁷¹. Both above studies suggest that *MTHFR* polymorphisms might enhance the environmental risks (low folate intake, traumatic stress at childhood) for MDD via the interaction between genetic and environmental factors. Such a risk was confirmed by a meta-analysis recruiting 26 published studies which showed an association between *MTHFR* C677T polymorphism and increased risk of depression⁷³. However, some studies showed no association between *MTHFR* and MDD or antidepressant treatment response^{74,75}.

Similarly, diverse situation existed in other researches as a study did not find evidence of an association between the *MTHFR* TT genotype and depression in a depression cohort⁷⁶. Another study including depressed subjects indicated no significant differences in frequency of the T allele or TT genotype between the depressed and healthy controls⁷⁷. A research of TT genotype and depression scores revealed that the C677T gene variation does not play an important role in the depression scores⁷⁸. In a meta-analysis, no significant differences in genotype or allele frequencies between depressive patients and controls were observed⁷⁴.

A possible reason for divergent consequences is population stratification as the frequency of the T allele is subject to considerable ethnic and geographic variation⁷⁴. Another possibility is that there is an association of this SNP with another disease that is highly correlated with depression. Indeed it has been hypothesized that depression and vascular disease may be different manifestations of the same genetic substrates⁷⁹. Both of these conditions are a result of the interaction of multiple genetic factors and environment, involving multiple genes with small interactive and additive effects.

Autism disorder

Comparing to Schizophrenia and depression, relatively limited studies of *MTHFR* in autism have been conducted. Some studies showed higher frequency of C677T polymorphism in children with ASD than in healthy controls⁸⁰, or associated with ASD behavior phenotypes⁸¹. A risk study of ASD with typical development indicated significant interaction effects between maternal TT genotype and greater risk for ASD⁸², suggesting *MTHFR* polymorphism might involve the early development of ASD. Other studies in the Chinese Han and Korean

population also found that *MTHFR* C677T and A1298C mutation genes were risk factors for autism in Chinese Han children and Korean population, respectively^{83,84}.

Attention deficit hyperactivity disorder (ADHD)

In terms of the relationship between *MTHFR* and ADHA, only very few studies have been reported, even with controversial findings. For example, studies demonstrated that A1298C genotype appeared to be the predominant linkage to the inattentive symptoms, leading to a 7.4-fold increase in ADHD, compared with a 1.3-fold increase for the C677T genotype⁸⁵, individuals with ADHD seem to be related to A1298C polymorphisms⁸⁶. However, a research with ADHD and healthy controls reported no association between C677T or A1298C polymorphism and ADHD in Turkish children⁸⁷. Further studies with large sample size or better controls are needed.

In conclusion, *MTHFR* polymorphism not only increase risks for diabetes, cardiovascular diseases, and various cancers, but also increase the risk for various psychiatric diseases. For example, as we described above that *MTHFR* polymorphism is associated with early onset of schizophrenia and the severity of depressive symptoms in MDD. This is important since neurotransmitter imbalances hypotheses are still the main streams for schizophrenia and MDD. Understanding alternative mechanisms of psychiatric diseases will not only provide potential biomarkers for specific psychiatric diseases, but also new targets for antipsychotic drug development. Due to significant controversial findings in *MTHFR* mutation and DNA methylation in both healthy populations and psychiatric patients, investigation of *MTHFR* activity in peripheral samples might be important. As yet, the relationships between enzymatic activity and mutation of *MTHFR* have been reported in general healthy and mental retardation populations as well as in animals, no studies have been found in clinical test of *MTHFR* activity in psychiatric patients^{88–90}. In addition, there are still some shortages on *MTHFR* mutation and psychiatric disease studies. Except for C677T and A1298C, there were little studies on other SNPs as well as the effect of multiple SNPs on the diseases which may also affect *MTHFR* activity.

Clinical treatment strategy for *MTHFR*-related psychiatric disorders

As *MTHFR* plays a critical role in one-carbon metabolism, which is composed of folate, homocysteine, vitamin B12, and methylation of DNA, mutation of specific gene locus on *MTHFR* and correlative enzyme activity decline will affect various of physiological events as well as some pathology states, including psychiatric disorders. Whether we could cope with gene mutation and enzyme

activity damage using folate one-carbon metabolism strategy as clinical treatment for MTHFR-related psychiatric disease? Some studies showed some interesting possibilities. For example, studies of healthy females found that the low level of serum folate in 677TT genotype is associated with an increase in homocysteine concentration and DNA hypomethylation^{91,92}, which reveals the association between *MTHFR* C677T polymorphisms and nutrient status. As food is a major resource for folate, studies reported that low folate level due to unbalanced diet is associated with higher prevalence on schizophrenia, particularly in infants with maternal nutritional deficiency^{11,93}. Another study exploring the association between folate and symptoms of schizophrenia indicated that low folate was associated with negative symptoms severity in schizophrenia subjects⁹⁴. One possible role of folate in mental health is its action on DNA methylation and gene expression which have been widely reported in human psychiatric disorders.

As *MTHFR* polymorphisms-induced MTHFR activity decline is irreversible, clinicians tried to use supplement of folate to help methylation process and change the pathogenesis state. For instance, methylfolate supplement was used for the improvement of psychiatric symptoms⁹⁵, while folate supplementation showed reduction of the incidence of neural tube defects which reduces the incidence of schizophrenia⁹⁶. Although there is no evidence that supplements are helpful in the treatment of psychosis in general, based on the published studies, we believe that if we can detect *MTHFR* polymorphism in individuals with various psychiatric diseases, we might be able to differentiate those MTHFR-related psychiatric patients from non MTHFR deficient patients and develop specific clinical treatment strategies, such as folate or methylfolate supplement to reverse the symptoms. In summary, due to the higher frequency of *MTHFR* polymorphism in various psychiatric disease, supplement of folate and cobalamin might be critical when patients with MTHFR deficiency. MTHFR deficiency-related psychiatric diseases should be identified and might be able to be treated with targeted supplement for the diseases and related symptoms.

Conclusions

Increasing evidence demonstrated that *MTHFR* polymorphism including C677T and A1298C is associated with psychiatric diseases. The *MTHFR* gene polymorphism is linked to onset, clinical symptoms, prevalence as well as response to treatments. The influence of *MTHFR* on psychiatric diseases is mainly through reduction of MTHFR activity which results in elevation of homocysteine, reduction of DNA methylation-dependent methyl donor, finally induces hypomethylation, and then active disease-related genes. However, some age- and cell

type-specific methylation seems independent from *MTHFR* polymorphism. *MTHFR* mutation also can increase environmental risks for psychiatric disorders, such as MDD through interaction between genetic and epigenetic factors. Investigation of MTHFR in psychiatric diseases has important clinical implications, such as identification role of *MTHFR* and its genotypes in the psychiatric patients who respond or not respond to traditional pharmacological treatment for personalized treatment management of psychiatric diseases.

Acknowledgements

We thank all researchers and colleagues from Key Laboratory of Molecular Biology in Beijing Anding Hospital of Capital Medical University and Beijing Institute for Brain Disorders for their great support

Author details

¹Center for Brain Disorders Research, Capital Medical University & Beijing Institute of Brain Disorders, Beijing 100069, China. ²The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China. ³Center for Hormone Advanced Science and Education, Roskamp Institute, Sarasota, FL 34243, USA

Competing interests

The authors declare that they have no conflict of interest.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 24 January 2018 Revised: 7 August 2018 Accepted: 10 September 2018

Published online: 05 November 2018

References

1. Froese, D. S. et al. Mutation update and review of severe methylenetetrahydrofolate reductase deficiency. *Hum. Mutat.* **37**, 427–438 (2016).
2. Oztuzcu, S. et al. Evaluation of Factor V G1691A, prothrombin G20210A, Factor XIII V34L, MTHFR A1298C, MTHFR C677T and PAI-1 4G/5G genotype frequencies of patients subjected to cardiovascular disease (CVD) panel in south-east region of Turkey. *Mol. Biol. Rep.* **41**, 3671–3676 (2014).
3. Ferrara, M., Capozzi, L. & Russo, R. Impact of the MTHFR C677T polymorphism on risk of Wilms tumor: case-control study. *J. Pediatr. Hematol. Oncol.* **31**, 256–258 (2009).
4. Mansoori, N., Tripathi, M., Luthra, K., Alam, R., Lakshmy, R. & Sharma, S. et al. MTHFR (677 and 1298) and IL-6-174 G/C genes in pathogenesis of Alzheimer's and vascular dementia and their epistatic interaction. *Neurobiology of Aging* **33**, 1003.e1–1003.e8 (2012).
5. An, X. K. et al. Association of MTHFR C677T polymorphism with susceptibility to migraine in the Chinese population. *Neurosci. Lett.* **549**, 78–81 (2013).
6. Yoshimi, A. et al. Gene-wide association study between the methylenetetrahydrofolate reductase gene (MTHFR) and schizophrenia in the Japanese population, with an updated meta-analysis on currently available data. *Schizophr. Res.* **124**, 216–222 (2010).
7. Saetre, P. et al. Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and age of onset in schizophrenia: a combined analysis of independent samples. *Am. J. Med Genet B Neuropsychiatr. Genet* **156**, 215–224 (2011).
8. Muntjewerff, J. W. et al. Effects of season of birth and a common MTHFR gene variant on the risk of schizophrenia. *Eur. Neuropsychopharmacol.* **21**, 300–305 (2011).
9. Muntjewerff, J. W. et al. No evidence for a preferential transmission of the methylenetetrahydrofolate reductase 677T allele in families with

- schizophrenia offspring. *Am. J. Med Genet B Neuropsychiatr. Genet* **144B**, 891–894 (2007).
10. Klengel, T., Pape, J., Binder, E. B. & Mehta, D. The role of DNA methylation in stress-related psychiatric disorders. *Neuropharmacology* **80**, 115–132 (2014).
 11. St Clair, D. et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959–1961. *JAMA* **294**, 557–562 (2005).
 12. Tran, P. et al. Multiple transcription start sites and alternative splicing in the methylenetetrahydrofolate reductase gene result in two enzyme isoforms. *Mamm. Genome* **13**, 483–492 (2002).
 13. Goyette, P. P. A. & Milos, R. et al. Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). *Mamm. Genome* **9**, 652–656 (1998).
 14. Liew, S. C. & Gupta, E. D. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. *Eur. J. Med Genet* **58**, 1–10 (2015).
 15. van der Put, N. M. et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? *Am. J. Hum. Genet* **62**, 1044–1051 (1998).
 16. Robert Pejchal, E. C. et al. Structural perturbations in the Ala-Val polymorphism of methylenetetrahydrofolate reductase—how binding of folates may protect against inactivation. *Biochemistry* **45**, 4808–4818 (2006).
 17. Kazuhiro Yamada, Z. C., Rima, R. & Rowena Mathews, G. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. *Proc. Natl Acad. Sci. USA* **98**, 14853–14858 (2001).
 18. Selhub, P.J.B. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. *Proc Natl Acad Sci USA* **95**, 13217–13220 (1998).
 19. Trimmer, E. Methylenetetrahydrofolate reductase: biochemical characterization and medical significance. *Curr. Pharm. Des.* **19**, 2574–2593 (2013).
 20. Yamada, K., Strahler, J. R., Andrews, P. C. & Matthews, R. G. Regulation of human methylenetetrahydrofolate reductase by phosphorylation. *Proc. Natl Acad. Sci. USA* **102**, 10454–10459 (2005).
 21. G. Matthews, D. A. Ja Allosteric inhibition of methylenetetrahydrofolate reductase by adenosylmethionine. *J. Biol. Chem.* **262**, 2485–2493 (1987).
 22. Krebs, M. O., Bellon, A., Mainguy, G., Jay, T. M. & Frieling, H. One-carbon metabolism and schizophrenia: current challenges and future directions. *Trends Mol. Med* **15**, 562–570 (2009).
 23. de Arruda, I. T., Persuhn, D. C. & de Oliveira, N. F. The MTHFR C677T polymorphism and global DNA methylation in oral epithelial cells. *Genet Mol. Biol.* **36**, 490–493 (2013).
 24. Frosst, P. B. H. et al. A candidate genetic risk factor for vascular disease—a common mutation in methylenetetrahydrofolate reductase. *Nat. Genet* **1994**, 111–113 (1995).
 25. Philippe Goyette, B., & David S, R. & Rozen, R. Severe and mild mutations in cis for the Methylenetetrahydrofolate Reductase (MTHFR) gene, and description of five novel mutations in MTHFR. *Am. J. Human. Genet.* **59**, 1268–1275 (1996).
 26. Ilan Weisberg, P. T., Benedicte, C., Sahar, S. & Rima Rozen, A. Second genetic polymorphism in Methylenetetrahydrofolate Reductase (MTHFR) associated with decreased enzyme activity. *Mol. Genet. Metab.* **64**, 169–172 (1998).
 27. Brian, D. et al. The structure and properties of methylenetetrahydrofolate reductase from *Escherichia coli* suggest how folate ameliorates human hyperhomocysteinemia. *Nat. Struct. Biol.* **6**, 359 (1999).
 28. Friso S, C. S. W. et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. *Proc. Natl Acad. Sci. USA* **99**, 5606–5611 (2002).
 29. Choi, L. S. J. M. J. S. S. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. *Cancer Epidemiol. Biomark. Prev.* **9**, 849 (2000).
 30. Marcus, V. M. & et al. Age-related changes in the global DNA methylation profile of leukocytes are linked to nutrition but are not associated with the MTHFR C677T genotype or to functional capacities. *Plos ONE* **7**, e25270 (2012).
 31. Isabela Tatiana Sales de Arruda, D. C. Pa. N. F. Pd. O. The MTHFR C677T polymorphism and global DNA methylation in oral epithelial cells. *Genet. Mol. Biol.* **36**, 490–493 (2013).
 32. Narayanan, S. et al. Associations between two common variants C677T and A1298C in the methylenetetrahydrofolate reductase gene and measures of folate metabolism and DNA stability (strand breaks, misincorporated uracil, and DNA methylation status) in human lymphocytes in vivo. *Cancer Epidemiol. Biomark. Prev.* **13**, 1436–1443 (2004).
 33. Hanks, J. et al. The association between MTHFR 677C>T genotype and folate status and genomic and gene-specific DNA methylation in the colon of individuals without colorectal neoplasia. *Am. J. Clin. Nutr.* **98**, 1564–1574 (2013).
 34. Louie, K. et al. Evaluation of DNA methylation at imprinted DMRs in the spermatozoa of oligozoospermic men in association with MTHFR C677T genotype. *Andrology* **4**, 825–831 (2016).
 35. Zhu, Q. et al. Impact of MTHFR gene C677T polymorphism on Bcl-2 gene methylation and protein expression in colorectal cancer. *Scand. J. Gastroenterol.* **46**, 436–445 (2011).
 36. Huan Cheng, Z. D., Zengjun, W., Wei, Z. & Jiantang, S. MTHFR C677T polymorphisms are associated with aberrant methylation of the IGF-2 gene in transitional cell carcinoma of the bladder. *J. Biomed. Res.* **26**, 77–83 (2012).
 37. Xia, Y., & Song, B. & Kong, X. & Liu, D. & Li, J. Aberrant DNA Methylation of P16, MGMT, and hMLH1 Genes in Combination with MTHFR C677T Genetic Polymorphism in gastric cancer. *Pak J Med Sci* **29**, 1338–1343 (2013).
 38. Lawrance, A. K. et al. Complete deficiency of methylenetetrahydrofolate reductase in mice is associated with impaired retinal function and variable mortality, hematological profiles, and reproductive outcomes. *J. Inherit. Metab. Dis.* **34**, 147–157 (2011).
 39. Schwahn, B. C. et al. Betaine rescue of an animal model with methylenetetrahydrofolate reductase deficiency. *Biochem J.* **382**, 831–840 (2004).
 40. Christensen, B. et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. *Arter. Thromb Vas* **17**, 569–573 (1997).
 41. Chen Z, K. A. C. et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. *Human. Mol. Genet.* **10**, 433 (2001).
 42. Freeman, J. M., Finkelstei, J. D. & Mudd, S. H. Folate-responsive homocystinuria and “schizophrenia”. *Nutr. Rev.* **40**, 242–245 (2010).
 43. Burghardt, K. J., Pilsner, J. R., Bly, M. J. & Ellingrod, V. L. DNA methylation in schizophrenia subjects: gender and MTHFR 677C/T genotype differences. *Epigenomics* **4**, 261–268 (2012).
 44. Lewis, S. J., Zammit, S., Gunnell, D. & Smith, G. D. A meta-analysis of the MTHFR C677T polymorphism and schizophrenia risk. *Am. J. Med Genet B Neuropsychiatr. Genet* **135B**, 2–4 (2005).
 45. Muntjewerff, J. W. et al. Hyperhomocysteinemia, methylenetetrahydrofolate reductase 677TT genotype, and the risk for schizophrenia: a Dutch population based case-control study. *Am. J. Med Genet B Neuropsychiatr. Genet* **135B**, 69–72 (2005).
 46. Kempisty, B. et al. Association of 677C>T polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene with bipolar disorder and schizophrenia. *Neurosci. Lett.* **400**, 267–271 (2006).
 47. Roffman, J. L. et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. *Biol. Psychiatry* **63**, 42–48 (2008).
 48. Roffman, J. L. et al. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. *Schizophr. Res.* **92**, 181–188 (2007).
 49. Schiepers O J, vB. M. P. et al. Genetic variation in folate metabolism is not associated with cognitive functioning or mood in healthy adults. *Progress. Neuro-Psychopharmacol. Biol. Psychiatry* **35**, 1682–1688 (2011).
 50. Vares, M. et al. Association between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and age of onset in schizophrenia. *Am. J. Med Genet B Neuropsychiatr. Genet* **153B**, 610–618 (2010).
 51. Lajin, B., Alhaj Sakur, A., Michati, R. & Alachkar, A. Association between MTHFR C677T and A1298C, and MTRR A66G polymorphisms and susceptibility to schizophrenia in a Syrian study cohort. *Asian J. Psychiatry.* **5**, 144–149 (2012).
 52. Zhang, Y. et al. Association of MTHFR C677T polymorphism with schizophrenia and its effect on episodic memory and gray matter density in patients. *Behav. Brain Res* **243**, 146–152 (2013).
 53. Nishi, A. et al. Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. *Schizophr. Bull.* **40**, 1154–1163 (2014).
 54. Yadav, U., Kumar, P., Gupta, S. & Rai, V. Role of MTHFR C677T gene polymorphism in the susceptibility of schizophrenia: an updated meta-analysis. *Asian J. Psychiatry* **20**, 41–51 (2016).

55. da Silva, T. L. & Ravindran, A. V. Contribution of sex hormones to gender differences in schizophrenia: a review. *Asian J. Psychiatr.* **18**, 2–14 (2015).
56. Salokangas, R. K. R. Gender and the use of neuroleptics in schizophrenia. *Schizophr. Res.* **66**, 41–49 (2004).
57. Ebinger, M., Sievers, C., Ivan, D., Schneider, H. J. & Stalla, G. K. Is there a neuroendocrinological rationale for testosterone as a therapeutic option in depression? *J. Psychopharmacol.* **23**, 841–853 (2009).
58. Lee, D. et al. Progesterone modulation of D5 receptor expression in hypothalamic ANP neurons, the role of estrogen. *Mol. Psychiatry* **6**, 112–117 (2001).
59. Zhang, C. et al. Further evidence that methylenetetrahydrofolate reductase A1298C polymorphism is a risk factor for schizophrenia. *J. Neural Transm. (Vienna)* **117**, 1115–1117 (2010).
60. Zhang, C. et al. Influence of maternal MTHFR A1298C polymorphism on the risk in offspring of schizophrenia. *Brain Res* **1320**, 130–134 (2010).
61. Roffman, J. L. et al. Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. *Schizophr. Bull.* **39**, 330–338 (2013).
62. El-Hadidy, M. A., Abdeen, H. M., Abd El-Aziz, S. M. & Al-Harrass, M. MTHFR gene polymorphism and age of onset of schizophrenia and bipolar disorder. *Biomed. Res Int* **2014**, 318483 (2014).
63. Peerbooms, O. L. et al. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability? *Brain Behav. Immun.* **25**, 1530–1543 (2011).
64. Chen, Z. et al. C677T methylenetetrahydrofolate reductase gene polymorphisms in bipolar disorder: an association study in the Chinese population and a meta-analysis of genetic association studies. *Neurosci. Lett.* **449**, 48–51 (2009).
65. Cohen-Woods, S. et al. The Bipolar Association Case-Control Study (BACCS) and meta-analysis: no association with the 5,10-Methylenetetrahydrofolate reductase gene and bipolar disorder. *Am. J. Med Genet B Neuropsychiatr. Genet* **153B**, 1298–1304 (2010).
66. Arzaghi, S. M., Shariat, A. H.-N. S. V., Ghodsipour, A., Shams, J. & Larijani, B. C677T Methylenetetrahydrofolate Reductase (MTHFR) gene polymorphism in schizophrenia and bipolar disorder—an association study in Iranian population. *Iran. J. Psychiatry* **6**, 1–6 (2011).
67. Kelly, C. B. M. A. P. & Johnston, T. G. et al. The MTHFR C677T polymorphism is associated with depressive episodes in patients from Northern Ireland. *J. Psychopharmacol.* **18**, 567 (2004).
68. Bousman, C. A. P. M. et al. Methylenetetrahydrofolate Reductase (MTHFR) genetic variation and major depressive disorder prognosis—a five-year prospective cohort study of primary care attendees. *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.* **165**, 68–76 (2013).
69. Folate, E. V. S. vitamin B12 and homocysteine, and the MTHFR 677C>T polymorphism in anxiety and depression. The Hordaland Homocysteine Study. *Arch. Gen. Psychiatry* **60**, 618–626 (2003).
70. Slopian, R. J. K. et al. Polymorphic variants of genes encoding MTHFR, MTR, and MTHFD1 and the risk of depression in postmenopausal women in Poland. *Maturitas* **61**, 252–255 (2008).
71. Lok, A. B. C. L. H. & Koeter, M. W. J. et al. Interaction between the MTHFR C677T polymorphism and traumatic childhood events predicts depression. *Transl. Psychiatry* **3**, e288 (2013).
72. Delport, D. et al. Significance of dietary folate intake, homocysteine levels and MTHFR 677 C>T genotyping in South African patients diagnosed with depression: test development for clinical application. *Metab. Brain Dis.* **29**, 377–384 (2014).
73. Wu, Y. L. et al. Association between MTHFR C677T polymorphism and depression: an updated meta-analysis of 26 studies. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **46**, 78–85 (2013).
74. Gaysina, D. et al. No association with the 5,10-methylenetetrahydrofolate reductase gene and major depressive disorder: results of the depression case control (DeCC) study and a meta-analysis. *Am. J. Med Genet B* **147b**, 699–706 (2008).
75. Shen, X. et al. Association analysis of COMT/MTHFR polymorphisms and major depressive disorder in Chinese Han population. *J. Affect Disord.* **161**, 73–78 (2014).
76. Moorthy, D. et al. Status of vitamins B-12 and B-6 but not of folate, homocysteine, and the methylenetetrahydrofolate reductase C677T polymorphism are associated with impaired cognition and depression in adults. *J. Nutr.* **142**, 1554–1560 (2012).
77. Lizer, M. H., Bogdan, R. L. & Kidd, R. S. Comparison of the frequency of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in depressed versus nondepressed patients. *J. Psychiatr. Pract.* **17**, 404–409 (2011).
78. Almeida, O. P. et al. Contribution of the MTHFR gene to the causal pathway for depression, anxiety and cognitive impairment in later life. *Neurobiol. Aging* **26**, 251–257 (2005).
79. Bondy, B. et al. Combined action of the ACE D- and the G-protein beta3 T-allele in major depression: a possible link to cardiovascular disease? *Mol. Psychiatry* **7**, 1120–1126 (2002).
80. Pasca, S. P. et al. One carbon metabolism disturbances and the C677T MTHFR gene polymorphism in children with autism spectrum disorders. *J. Cell Mol. Med* **13**, 4229–4238 (2009).
81. Goin-Kochel, R. P. et al. The MTHFR 677C->T polymorphism and behaviors in children with autism: exploratory genotype-phenotype correlations. *Autism Res* **2**, 98–108 (2009).
82. Schmidt, R. J. et al. Prenatal vitamins, one-carbon metabolism gene variants, and risk for autism. *Epidemiology* **22**, 476–485 (2011).
83. Guo, T., Chen, H., Liu, B., Ji, W. & Yang, C. Methylenetetrahydrofolate reductase polymorphisms C677T and risk of autism in the Chinese Han population. *Genet Test. Mol. Biomark.* **16**, 968–973 (2012).
84. Park, J. et al. MTHFR 1298A > C is a risk factor for autism spectrum disorder in the Korean population. *Psychiatry Res* **215**, 258–259 (2014).
85. Krull, K. R. et al. Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors. *J. Pediatr.* **152**, 101–105 (2008).
86. Gokcen, C. K. N. & Pekgor, A. Methylenetetrahydrofolate reductase gene polymorphisms in children with attention deficit hyperactivity disorder. *Int. J. Med. Sci.* **8**, 523–528 (2011).
87. Ergul, E., Sazci, A. & Kara, I. Methylenetetrahydrofolate reductase gene polymorphisms in Turkish children with attention-deficit/hyperactivity disorder. *Genet Test. Mol. Biomark.* **16**, 67–69 (2012).
88. Engbersen, A. M. T. et al. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. *Am. J. Human Genet.* **56**, 142–150 (1995).
89. Yano, H. et al. Mutations of the MTHFR gene (428C>T and [458G>T+459C>T]) markedly decrease MTHFR enzyme activity. *Neurogenetics* **5**, 135–140 (2004).
90. Huang, L., Zhang, J., Hayakawa, T. & Tsuge, H. Assays of methylenetetrahydrofolate reductase and methionine synthase activities by monitoring 5-methyltetrahydrofolate and tetrahydrofolate using high-performance liquid chromatography with fluorescence detection. *Anal. Biochem* **299**, 253–259 (2001).
91. Kauwell, G. P. et al. Methylenetetrahydrofolate reductase mutation (677C->T) negatively influences plasma homocysteine response to marginal folate intake in elderly women. *Metabolism* **49**, 1440–1443 (2000).
92. Rampersaud, G. C. et al. Methylation decreases in response to moderate folate depletion in elderly women. *Am. J. Clin. Nutr.* **72**, 998–1003 (2000).
93. Susser, E. et al. Schizophrenia after prenatal famine—further evidence. *Arch. Gen. Psychiatr.* **53**, 25–31 (1996).
94. Goff, D. C. et al. Folate, homocysteine, and negative symptoms in schizophrenia. *Am. J. Psychiatry* **161**, 1705–1708 (2004).
95. Godfrey, P. S. et al. Enhancement of recovery from psychiatric illness by methylfolate. *Lancet* **336**, 392–395 (1990).
96. Picker, J. D. & Coyle, J. T. Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase risk for schizophrenia? *Harv. Rev. Psychiatry* **13**, 197–205 (2005).
97. Kontis, D. et al. COMT and MTHFR polymorphisms interaction on cognition in schizophrenia: an exploratory study. *Neurosci. Lett.* **537**, 17–22 (2013).
98. AR, Lewis S. J. et al. Folic acid supplementation during pregnancy may protect against depression 21 months after pregnancy, an effect modified by MTHFR C677T genotype. *Eur. J. Clin. Nutr.* **66**, 97–103 (2012).
99. Schmidt, R. J. et al. Maternal periconceptual folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (Childhood Autism Risks from Genetics and Environment) case-control study. *Am. J. Clin. Nutr.* **96**, 80–89 (2012).
100. dos Santos, P. A. L. D. et al. MTHFR C677T is not a risk factor for autism spectrum disorders in South Brazil. *Psychiatr. Genet.* **20**, 187–189 (2010).
101. Sener, E. F., Oztop, D. B. & Ozkul, Y. MTHFR gene C677T polymorphism in autism spectrum disorders. *Genet Res Int* **2014**, 698574 (2014).
102. Saha, T., Chatterjee, M. & Sinha, S. & Rajamma, U. & Mukhopadhyay, K. Components of the folate metabolic pathway and ADHD core traits: an exploration in eastern Indian probands. *J Hum Genet* **62**, 687–695 (2017).